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The use of vancomycin for the treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) infections ([@B1], [@B2]) has been challenged by the emergence of vancomycin-intermediate ([@B3]) and -resistant ([@B4], [@B5]) *S. aureus* (VISA and VRSA, respectively). We reported on a heterogeneous vancomycin-intermediate *S. aureus* (hVISA) strain (MM66) isolated from a hospital in Las Cruces, New Mexico, that when grown in the presence of vancomycin gave rise to stable VISA subpopulations ([@B6]). In order to provide insight on the MM66 hVISA mechanism, we have completed and compared the draft genomes of MM66, an MM66 VISA (MM66-4) ([@B6]), and a reduced vancomycin-intermediate (RVI) MM66 isolate (MM66RVI-4).

MM66RVI-4 was obtained by passaging MM66 in Luria broth (LB) and selecting for colonies unable to grow on LB agar containing 1 µg/ml vancomycin. The DNA of all strains was isolated from overnight cultures (37° C, 200 rpm) grown in Mueller-Hinton broth (MHB). Draft genomes of MM66 and MM66RVI-4 were produced with the Roche 454 GS (Junior) pyrosequencing platform and assembled using the Roche GS *de novo* assembler (v. 2.7). Libraries of MM66 and MM66-4 were constructed with the phusion-based Illumina genomic DNA library preparation protocol and sequenced using Illumina genome analyzer II 90-bp paired-end reads. *De novo* assembly was generated using filtered sequence reads and the ABySS assembler (v. 1.3.7) ([@B7]). All genome sequences were uploaded to the RAST server for annotation ([@B8]).

The vancomycin Etest MIC ([@B6]) of MM66RVI-4 and MM66 were 2 µg/ml and 3 µg/ml, respectively. MM66RVI-4 also demonstrated decreased distances grown on 0 to 3 µg/ml vancomycin (41.6 mm ± 3) and 0 to 3 µg/ml teicoplanin (16 mm ± 3) gradients ([@B9]) compared to MM66 (61.6 mm ± 4, and 30.6 mm ± 4, respectively (*n* = 3; *P* ≤ 0.05). In addition, MM66RVI-4 did not grow as well in MHB containing 2.5 µg/ml vancomycin and demonstrated reduced cell survival in vancomycin resistance population analysis ([@B9]) (0 to 3.5 µg/ml) performed with MH agar. Furthermore, whereas MM66 grew on a 0 to 175 µg/ml oxacillin gradient (84.0 mm ± 2), MM66RVI-4 grew only on a 0 to 0.5 µg/ml gradient (73 mm ± 5).

Draft genome information for all strains is summarized in [Table 1](#T1){ref-type="table"}. The number of RAST predicted protein-coding sequences were 2,684 (454) and 2,858 (Illumina) for MM66 and 2,563 and 2,814 for MM66RVI-4 and MM66-4, respectively. All strains sequenced were multilocus sequence type 5 (ST-5) and staphylococcal cassette chromosome *mec* type II (SCC*mec*II) ([@B10], [@B11]). The isolation ST-5/SCC*mec*II strains in the Las Cruces area have been previously reported ([@B12], [@B13]). The loss of oxacillin resistance in MM66RVI-4 is corroborated by an \~46.5-kb deletion of SCC*mec*II that remains in MM66 and MM66-4. Selection for VISA in the laboratory can also lead to SCC*mec* loss ([@B14], [@B15]). Mutations in genes encoding the two-component GraSR system are thought to support the VISA mechanism ([@B16][@B17][@B19]) and all MM66 derivatives harbored the same mutation in *graS* (S270N). In addition, mutations within *apt* and *yycG* of MM66-4 ([@B20]) were confirmed.

###### 

*Staphylococcus aureus* genome assembly and accession numbers

  Strain      Sequence coverage (%)                      No. of contigs (bp)   *N*~50~ (Mbp)   Genome length (bp)   GC content (%)   Accession no.
  ----------- ------------------------------------------ --------------------- --------------- -------------------- ---------------- ---------------
  MM66        30.1^*[a](#TF1-1){ref-type="table-fn"}*^   114 (\>200)           0.17            2,834,320            32.9             JMBT00000000
  MM66        348^*[b](#TF1-2){ref-type="table-fn"}*^    90 (\>1,000)          0.09            3,002,171            33.0             CCCM000000000
  MM66RVI-4   36.6^*[a](#TF1-1){ref-type="table-fn"}*^   197 (\>200)           0.21            2,732,996            33.0             JMBU00000000
  MM66-4      612^*[b](#TF1-2){ref-type="table-fn"}*^    73 (\>1,000)          0.15            2,940,194            32.8             CCCI000000000

454 sequence coverage.

Illumina sequence coverage.

Nucleotide sequence accession numbers. {#h1}
--------------------------------------

These whole-genome shotgun projects have been deposited at DDBJ/EMBL/GenBank under the accession numbers [JMBT00000000](JMBT00000000), [CCCM000000000](CCCM000000000), [JMBU00000000](JMBU00000000), and [CCCI000000000](http://www.ncbi.nlm.nih.gov/nuccore/CCCI000000000).
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